First Access

If you’ve subscribed to First Access, please click the stars below to indicate your rating for this newsletter, and please share any other feedback about your experience using the comment box below.

Investment Performance

No votes yet... cast yours!
No votes yet.
Please wait...
Your vote

Quality Of Writing/Analysis

No votes yet... cast yours!
No votes yet.
Please wait...
Your vote

Value For Price

No votes yet... cast yours!
No votes yet.
Please wait...
Your vote

Customer Service

No votes yet... cast yours!
No votes yet.
Please wait...
Your vote

3
Share your thoughts...

avatar
3 Comment threads
0 Thread replies
0 Followers
 
Most reacted comment
Hottest comment thread
3 Comment authors
R. M. KribsJeff  Abbottdon johnson Recent comment authors

This site uses Akismet to reduce spam. Learn how your comment data is processed.

don johnson
Guest
don johnson

i think if a listing of co’s and dates of fda info releases were known we could all be millionaires with a few good guesses!! what a lottery this is!!

Add a Topic
3022
Jeff  Abbott
Guest
Jeff Abbott

Don’t know anything about this newsletter but i can tell you that Sangamo is the real deal in terms of a quality Biotech, quality science with a unique and impressive platform(zinc finger). It is a highly recommended and followed small cap developmental biotech with an impressive pipeline. That being said no matter how impressive the science, trial stages are always a crapshoot, especially the more advanced that are. I follow this company and it’s science fairly closely and my opinion is that they will show positive,significant results in their IIB results but i do not think it will be worth… Read more »

Add a Topic
5971
R. M. Kribs
Guest
R. M. Kribs

I have never had First Access, but have been stung by Marc Lichtenfeld when he wrote about Accuray (ARAY) for Xcelerated Profits. I was supposed to get a 119% return, but got a loss instead–& don`t know why. ARAY has a unique product in it`s Cyberknife, so should be worth more than $6-$7. Therefore, something must be wrong with management & as a Senior Analyst (?) Marc should have known that.

Add a Topic
1404
Add a Topic
655
Add a Topic
15
Edward M. Fischer
Guest

Louis is right much more often than wrong, but you have to be selective as you do with ANY news letter; follow his portfolio composition relative to YOUR comfort risk factor (conservative, moderately aggressive & aggressive). I test drove his August Blue Chip; picked 20 A ratings, buying 100 of each for $117,291. As of today $132,045 PROFIT of $14,754, UP 12.58%. AWESOME considering time frame includes a DEVASTATING Sept & Oct!! B happy to send the SmartMoney.com spreadsheet to anyone as proof.

Nigel
Guest
Nigel

Can you tell me more about these instuments? I have some experience with something I think may be similar, but didnt have a good outcome